

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 9/12	A1	(11) International Publication Number: WO 00/53157 (43) International Publication Date: 14 September 2000 (14.09.00)
(21) International Application Number: PCT/EP99/01449 (22) International Filing Date: 5 March 1999 (05.03.99) (71) Applicant (for all designated States except US): CHIESI FARMACEUTICI S.P.A. [IT/IT]; Via Palermo, 26/A, I-43100 Parma (IT). (72) Inventors; and (75) Inventors/Applicants (for US only): MUSA, Rossella [IT/IT]; Via Palermo, 26/A, I-43100 Parma (IT). VENTURA, Paolo [IT/IT]; Via Palermo, 26/A, I-43100 Parma (IT). CHIESI, Paolo [IT/IT]; Via Palermo, 26/A, I-43100 Parma (IT). (74) Agent: MINOJA, Fabrizio; Bianchetti Bracco Minoja S.R.L., Via Rossini, 8, I-20122 Milano (IT).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: IMPROVED POWDERY PHARMACEUTICAL COMPOSITIONS FOR INHALATION (57) Abstract The invention describes the use of a little percentage of lubricant (0.05–0.5 % by weight) in powdery pharmaceutical compositions for use in dry powder inhalers in order to increase the fine particle dose. A process for coating the surface of the carrier particles with such little amount of lubricant is also claimed. The use of limited amount of the lubricant is safe and allows to prepare ordered stable mixtures without segregation of the active particles during handling and before use.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

IMPROVED POWDERY PHARMACEUTICAL COMPOSITIONS FOR INHALATION

This invention relates to improved powdery pharmaceutical compositions for use in dry powder inhalers. The improvement is concerned with mechanical stability, performances and safety.

5 Inhalation anti-asthmatics are widely used in the treatment of reversible airway obstruction, inflammation and hyperresponsiveness.

Presently, the most widely used systems for inhalation therapy are the pressurised metered dose inhalers (MDIs) which use a propellant to expel droplets containing the pharmaceutical product to the respiratory tract.

10 However, despite their practicality and popularity, MDIs have some disadvantages:

- i) the majority of the dose released deposits in the oropharynx by impaction and only a small percentage penetrates directly into the lower lungs;
- 15 ii) the already small proportion of drug which penetrates the bronchial tree may be further reduced by poor inhalation technique;
- iii) last but not least, chlorofluorocarbons (CFCs), such as freons contained as propellants in MDIs, are disadvantageous on environmental grounds as they have a proven damaging effect on
20 the atmospheric ozone layer.

Dry powder inhalers (DPIs) constitute a valid alternative to MDIs for the administration of drugs to airways. The main advantages of DPIs are:

- i) being breath-actuated delivery systems, they do not require co-

ordination of actuation since release of the drug is dependent on the patient own inhalation;

- ii) they do not contain propellants acting as environmental hazards;
- iii) the quantity deposited by impaction in the oropharynx is lower.

5 DPIs can be divided into two basic types:

- i) single dose inhalers, for the administration of single subdivided doses of the active compound;
- ii) multidose dry powder inhalers (MDPIs), pre-loaded with quantities of active principles sufficient for longer treatment cycles.

10 MDPIs are considered more convenient to the patient than single dose DPIs, not only because they provide a number of doses sufficient for longer treatment cycles but also because of their ease of use and unobtrusiveness.

15 Dry powder dosage forms are generally formulated by mixing the cohesive micronised drug with coarse carrier particles, giving rise to ordered mixture where the micronised active particles adhere to the surface of the carrier particles whilst in the inhaler device.

20 The carrier material, most commonly lactose, makes the micronised powder less cohesive and improves its flowability, making easier handling the powder during the manufacturing process (pouring, filling etc.). During inhalation, the small drug particles separate from the surface of carrier particles and penetrates into the lower lungs, while the larger carrier particles are mostly deposited in the oropharyngeal cavity.

25 The redispersion of drug particles from the carrier surface is regarded as the most critical factor which governs the availability of the medicament to the lungs. This will depend on the mechanical stability of the powder mix and the way this is influenced by the adhesion

characteristics between the drug and the carrier and the external forces required to break up the non covalent bonds formed between adhering particles. Too strong bonds between adhering particles may prevent indeed the separation of the micronised drug particles from the surface of carrier
5 particles. In particular, the efficiency of the redispersion process is strictly dependent on the carrier surface properties, the actual particle size of both the drug and the carrier and the drug to carrier ratio. Consequently, different approaches aimed at modulating one or more of these parameters have been proposed to promote the release of the drug particles from the
10 carrier particles and, hence, to increase the percentage of the respirable fraction. In the prior art, the use of a ternary component, with lubricant or anti-adherent properties, has been also suggested as a solution of the technical problem.

Fisons patents GB 1242211 and GB 1381872 described powders for
15 inhalation obtained by simple mixing of a medicament with a particle size of less than 10 microns and a coarse carrier whose particle size falls in a well defined range. They also disclosed that it may be useful to coat the surfaces of the particles and/or carrier with pharmaceutically acceptable material, such as stearic acid or polymers for giving a sustained release
20 action to the medicament.

Chiesi WO A 87 05213 described a carrier, comprising a conglomerate of a solid water-soluble carrier and a lubricant, preferably 1% magnesium stearate, for improving the technological properties of the powder in such a way as to remedy to the reproducibility problems
25 encountered after the repeated use of the inhaler device.

Staniforth *et al.* (J. Pharm. Pharmacol. 34, 141-145, 1982) observed that magnesium stearate is able to modify the adhesion of salicylic acid to

sucrose but, the amount used (0.5-4.0%) destabilises the mixture to the extent that significant segregation occurs.

Kassem (London University Thesis, 1990) studied the effect of 1.5% w/w magnesium stearate or Aerosil 200 (trade name for colloidal silicon dioxide) on the de-aggregation of powders made of salbutamol sulphate and lactose. Although the 'respirable' fraction increased when magnesium stearate was added, the reported amount is too great and reduces the mechanical stability of the mixture before use. Furthermore, being magnesium stearate poorly water-soluble, its presence in such amount may rise some concerns as to a potential irritation or toxicity of this excipient, part of which can be inhaled by the patient together with the active ingredient. According to Staniforth (WO 96/23485), the reported drawbacks can be solved by adding physiologically acceptable/water-soluble additives with anti-adherent properties which do not make segregation of the active particles from the surfaces of the carrier particles during manufacturing of the dry powder and in the delivery device before use. In the said document, the anti-adherent material, preferably 1-2% leucine in particulate form, promote the release of the active particles by saturating the high energy sites of the carrier particles. Although it is generically disclosed that magnesium stearate, being highly surface active, should be added in particularly small amounts', the use of such excipient is considered not advisable.

It has now been discovered, and this is an object of the present invention, that lubricants like magnesium stearate can be advantageously and safely used as excipient for powdery pharmaceutical composition in such amount by weight based on the total weight of the powder of less than 0.5%; for steroids, the optimum amount of additive turned out to be

0.25%, whereas, for salbutamol base, it turned out to be 0.10%. Contrary to the teaching of the prior art (Peart *et al.* Pharm. Res. 14, S 142, 1997), 0.1% of magnesium stearate is sufficient for increasing in a significant way the fine particle dose, when salbutamol base instead of sulphate is used.

The invention also provides a method for producing a homogeneous carrier for powders for inhalation independently on the scale of mixing, the method including a step for coating the most as possible surface of the carrier particles with a little amount of lubricant. We have indeed found that it is advantageous to attain the highest as possible degree of coating of the carrier particles surface with the lubricant to increase the release of the active particles and, hence, the 'respirable' fraction. In the prior art, it was already known that the film forming properties of lubricants depend on the mixing time and significantly affect the compressibility characteristics of powders for tablets, but an advantageous relationship between the degree of coating and the 'respirable' fraction has never been reported before. We have also found, and this is another aspect of the invention, that use of lubricants in such little amount for coating the carrier, is sufficient for improving the flowability of the powder without causing mechanical stability problems of the mixture before use.

Finally we have found that the introduction of magnesium stearate in such a small amount is safe and does not produce any toxicologically relevant effect after repeated administration.

Advantageously the carrier of the invention is prepared by mixing the carrier particles and the lubricant particles for at least 2 min in a mixer in such a way as that no significant change in the particle size of the carrier particle occurs. Preferably, the carrier is mixed for at least 30 min

using a rotating body mixer with a rotating speed between 5 -100 r.p.m. or a stationary body mixer with a rotating mixing blade or a high-speed mixer. More preferably, the carrier is mixed for at least two hours in a Turbula mixer at 16 r.p.m..

- 5 Advantageously, the carrier particles and the lubricant particles are mixed until the degree of molecular surface coating is more than 10% as determined by water contact angle measurement. Preferably, carrier particles and lubricant particles made of magnesium stearate are mixed until the water contact angle of the 'coated' carrier particles is more than
10 36° corresponding to more than 15% degree of molecular surface coating; more preferably, the water contact angle should be more than 50° corresponding to more than 35% degree of molecular surface coating.

The carrier particles may be composed of any pharmacologically inert material or combinations of material acceptable for inhalation.

- 15 Advantageously, the carrier particles are composed of one or more crystalline sugars. Preferably, the carrier particles are particles of α -lactose monohydrate.

Advantageously, all the carrier particles have a particle size in the range 20-1000 μm , more preferably in the range 90-150 μm .

- 20 The preferred lubricant is any type of magnesium stearate which may be crystalline or amorphous; its use is described in the embodiments of the invention by way of examples which do not limit it in any way.

- Other lubricants, such as stearic acid, sodium lauryl sulphate, sodium stearyl fumarate, stearyl alcohol, sucrose monopalmitate and
25 sodium benzoate, could turn out to be suitable depending on the type of carrier and drug used.

Advantageously, at least 50% by weight of the lubricant particles

have a particle size more than 4 μm . Preferably, at least 60% of the lubricant particles made of magnesium stearate have a particle size more than 5 μm , with a specific surface area in the range 0.5-2.5 m^2/g measured by Malvern.

- 5 The ratio between the carrier and the drug are mixed will depend on the type of inhaler device used and the required dose.

Advantageously, the at least 90% of the particles of the drug have a particle size less than 10 μm , preferably less than 6 μm .

- 10 Drugs include those products which are usually administered by inhalation for the treatment of respiratory diseases, *i.e.* β -agonists, like salbutamol, formoterol, salmeterol, terbutaline and their salts, steroids like beclometasone dipropionate, flunisolide, budesonide, others like ipratropium bromide.

- 15 In a general aspect, the invention also provides a powdery pharmaceutical composition for use in a dry powder inhaler, the powder including active particles and a carrier where the surface of the carrier particles carrying the active particles is partially coated with a film of lubricant.

Example 1

- 20 Determination of the suitable amount of magnesium stearate to be added in beclomethasone-17,21-dipropionate (BDP) powders for inhalation

- 25 Samples of the carrier were prepared by mixing of α -lactose monohydrate (Meggler D 30) fraction 90-150 μm with 0.1%, 0.25% or 0.5% magnesium stearate for several hours in a Turbula mixer. Powders mixtures with different BDP concentrations (100, 200 and 400 $\mu\text{g}/\text{dose}$) were prepared by mixing of the carrier and the active ingredient for 30 min in a Turbula mixer at 32 r.p.m..

Multidose devices (Pulvinal[®]) filled with the mixtures were then tested by using a twin-stage impinger (TSI), Apparatus A (BP 93, Appendix XVII C, A194). The fine particle dose is calculated as a percentage of the total amount of drug delivered from the device (stage 1 + stage 2), that reaches stage 2 of TSI. The results are summarised in Tables 1, 2 and 3 (standard deviations, S.D., given in parentheses).

No significant increase in fine particle dose is obtained from increasing the concentration of magnesium stearate above 0.25%.

Table 1

Formulation (100 µg/dose)	Mg stearate (%)	Shot weight (mg)	Stage 2 (µg)	Delivered dose (µg)	Fine particle dose* (BDP %)
BDP 1	0.10	26.7 (0.3)	22.5 (3.5)	99.7 (0.6)	21.9 (2.8)
BDP 2	0.25	26.8 (0.1)	33.0 (5.6)	95.3 (0.6)	34.5 (6.2)

Table 2

Formulation (200 µg/dose)	Mg stearate (%)	Shot weight (mg)	Stage 2 (µg)	Delivered dose (µg)	Fine particle dose* (BDP %)
BDP 1	0	24.8 (0.4)	14.2 (5.7)	192 (14.0)	7.3 (2.6)
BDP 2	0.10	26.6 (0.4)	20.3 (4.6)	215 (2.3)	9.5 (2.2)
BDP 3	0.25	26.8 (0.6)	48.0 (8.5)	192 (7.8)	25.0 (3.7)
BDP 4	0.50	26.7 (0.2)	32.3 (2.3)	193 (4.6)	16.7 (1.0)

Table 3

Formulation (400 µg/dose)	Mg stearate (%)	Shot weight (mg)	Stage 2 (µg)	Delivered dose (µg)	Fine particle dose* (BDP %)
BDP 1	0	-	-	355 (22.8)	7.3 (0.4)
BDP 2	0.10	25.4 (0.3)	100 (11.0)	351 (4.5)	28.7 (3.4)
BDP 3	0.25	25.1 (0.4)	142 (22.1)	375 (9.3)	37.9 (5.7)
BDP 4	0.50	25.5 (0.3)	98 (44.7)	421 (18.4)	23.2 (10.3)

Example 2Determination of the suitable amount of magnesium stearate to be added in salbutamol base powders for inhalation

Samples of the carrier were prepared as reported in Example 1.

- 5 Powder mixtures containing 200 µg/dose of micronised salbutamol base were prepared by mixing of the carrier and the active ingredient for 30 min in a Turbula mixer at 32 r.p.m..

The powder mixtures were filled into inhalers and tested as reported in Example 1.

- 10 The results are summarised in Table 4.

0.1% Magnesium stearate is sufficient for increasing in a significant way ($t = 10.47$, $p < 0.001$) the fine particle dose, when salbutamol base instead of sulphate is used; no increase is obtained from increasing the concentration of magnesium stearate above this percentage.

Table 4

Formulation (200 µg/dose)	Mg stearate (%)	Shot weight (mg)	Stage 2 (µg)	Delivered dose (µg)	Fine particle dose* (Salbutamol %)
SALB 1	0	22.4 (0.4)	62.7 (5.3)	185 (5.1)	33.6 (2.9)
SALB 2	0.1	26.8 (0.5)	71.3 (3.1)	171 (5.0)	41.8 (0.9)
SALB 3	0.25	26.9 (0.2)	71.7 (6.1)	171 (1.7)	41.6 (3.2)
SALB 4	0.5	26.5 (0.5)	68.7 (6.4)	172 (6.0)	39.9 (3.5)

Example 3Determination of the suitable amount of magnesium stearate to be added in budesonide powders for inhalation

5 A sample of the carrier was prepared by mixing of α -lactose monohydrate (Meggle D 30) fraction 90-150 μ m with 0.25% magnesium stearate for two hours in Turbula T100 mixer at 16 r.p.m.

Powder mixtures containing 100 μ g/dose of micronised budesonide were prepared by mixing of the carrier and the active ingredient for 30 min in a Turbula mixer at 32 r.p.m..

10 The powder mixtures were filled into inhalers and tested as reported in Example 1.

The results are summarised in Table 5.

0.25% Magnesium stearate significantly increases the fine particle dose of budesonide ($t = 8.8$, $p < 0.001$);

Table 5

Formulation (100 µg/dose)	Mg stearate (%)	Shot weight (mg)	Stage 2 (µg)	Delivered dose	Fine particle dose* (µg) (Budesonide %)
BUD 1	0	22.0	-	80.0	21.4 (4.7)
BUD 2	0.25	21.5	-	79.3	33.6 (2.6)

* Average values obtained from three inhalers by actuating 5 shots from each inhaler.

Example 4Preparation of the carrier - Study of the mixing conditions

40.528 kg (99.75% w/w) of α -Lactose monohydrate fraction 90-150 μm and 0.102 kg (0.25 % w/w) of magnesium stearate were mixed in a
5 Turbula mixer T 100 at 16 r.p.m. for several hours. At different mixing times samples were withdrawn and tested for uniformity of distribution of magnesium stearate, particle size, water contact angle and degree of molecular surface coating calculated according to Cassie *et al.* (Transactions of the Faraday Society 40; 546, 1944). To validate the
10 process, three batches (40 kg) of the carrier were prepared.

The results are reported in Tables 6 and 7, respectively.

A uniform distribution of magnesium stearate was already achieved at 60 minutes blending time (mean value, \bar{x} , and coefficient of variation, CV%, are given); no significant change in the particle size was observed
15 after both Malvern light-scattering and Alpine sieving analyses. By increasing the mixing time, an increase of the degree of coating occurs.

The three different batches give comparable results.

Table 7

Mixing Time	Particle size Distribution (Alpine)		Particle size distribution (Malvern)		Magnesium stearate content uniformity		Water contact angle (degree)
	%<80μm	%<90μm	%<80μm	%<90μm	x (%)	CV (%)	
CARRIER 1							
10 min							34
20 min							37
30 min	1.5	4.8	0.9	2.7	0.228	6.8	36
60 min	0.3	2.8	0.9	2.6	0.235	6.1	36
90 min	0.6	3.8	1.0	2.9	0.244	3.7	37
120 min	0.7	3.4	0.9	2.7	0.239	7.2	39
CARRIER 2							
10 min							32
20 min							36
30 min							38
60 min	0.9	7.2	1.0	3.1	0.196	9.6	38
90 min							40
120 min	1.5	8.1	1.1	3.3	0.231	10.4	42
CARRIER 3							
10 min							32
20 min							31
30 min							33
60 min	0.8	6.9	2.0	4.5	0.237	7.3	38
90 min							42
120 min	0.8	7.3	1.8	4.2	0.229	3.8	42

Example 6Relationship between different mixing time of the carrier and delivered fine particle dose

40.528 kg (99.75% w/w) of α -Lactose monohydrate fraction 90-150 μm and 0.102 kg (0.25 % w/w) of magnesium stearate were mixed for several hours in Turbula T100 mixer at 16 r.p.m. At different mixing times, 2 kg samples were withdrawn and micronised BDP was added to each sample so that the nominal weight delivered by Pulvinal[®] inhaler contained 200 μg BDP. The powder mixtures were filled into inhalers and tested as reported in Example 1.

The results are reported in Table 8.

By increasing the mixing time, a significant increase at 420 min of the fine particle dose occurs ($t = 5.2$, $p < 0.001$).

Table 8

Formulation (BDP 200 µg/dose)	BDP 1	BDP 2	BDP 3
Mixing time (min)	60	120	420
Shot weight (mg)	27.8 (0.6)	28.1 (0.7)	28.2 (0.5)
Fine particle dose* (%)	34.1 (81)	37.4 (4.7)	49.5 (7.8)
Stage 2 (µg)	63.1 (12.0)	63.5 (8.1)	102.6 (17.1)
Delivered dose (µg)	188.4 (21.1)	169.7 (7.1)	207.2 (9.0)

*Average values obtained from three inhalers by actuating 5 shots from each inhaler

Example 7

Preparation of the carrier - Comparison between different mixers

40.528 kg (99.75% w/w) of α -Lactose monohydrate fraction 90-150 µm and 0.102 kg (0.25 % w/w) of magnesium stearate were mixed in a sigma-blade mixer for 30 min (water contact angle of 53° corresponding to 38% of molecular coating)

Powder mixtures containing 200 µg/dose of micronised BDP were prepared by mixing of the carrier and the active ingredient for 30 min in a Turbula mixer at 32 r.p.m..

The powder mixtures were filled into inhalers and tested as reported in Example 1.

The results are summarised in Table 9.

No significant difference was observed in the fine particle dose with respect to the powder obtained with the carrier prepared by using a Turbula mixer at 16 r.p.m. for 2 hours.

Table 9

Formulation (200 µg/dose)	Shot weight (mg)	Stage 2 (µg)	Delivered dose (µg)	Fine particle dose (BDP %)
Turbula mixer	25.7 (2.8)	96.2 (7.6)	167.5 (5.7)	57.4 (4.3)
Sigma-blade mixer	26.6 (2.3)	106.2 (11.2)	192.1 (7.0)	55.2 (6.0)

Example 8Segregation tendency of BDP bulk powder formulation containing 0.25% magnesium stearate

Composition of BDP Pulvinal[®] (100, 200 and 400 µg/dose):

Ingredient (mg)

	Strength (µg/dose)		
	100	200	400
BDP	0.100	0.200	0.400
α-Lactose monohydrate	25.832	25.735	25.536
Magnesium stearate	0.067	0.064	0.064

The tendency of the powder to segregate was assessed according to Staniforth *et al.* J. (Pharm. Pharmacol. 34, 700-706, 1982).

Approximately 15 g of powder was filled into a small plastic cylinder, 80 mm long and 12 mm in diameter, closed at one end and which could be split along its axis. This allowed the characterisation of both BDP and magnesium stearate on the same level in the same bulk mixture. The tube was mounted in a vibrator (Derrinton VP4) and vibrated at 50 Hz at a force of 2 g for ten minutes. The tube was then placed in a horizontal position, divided and 15 samples, each of about 50 mg accurately weighed, taken from along its length. The samples were analysed for BDP by HPLC and for magnesium stearate by atomic absorption. The experiments were carried out in duplicate. The results are reported in Tables 10 and 11.

Typical values in coefficient of variation (CV) of BDP samples drawn from a mix judged to be satisfactory are $\leq 5.0\%$. After the

imposition of an enhanced gravitational stress, BDP samples show a CV which varies from 2.7% and 7.8%. Despite the intense vibration, these variations have not increased significantly and are consistent with good inhaler performance when judged in terms of dose uniformity. Samples taken from the top of the bed are very similar to the bottom samples.

In the case of magnesium stearate, variability between samples was somewhat greater than for BDP due to its lower concentration. However, no consistent change in the uniformity of distribution occurred after vibration and, as with BDP, the content of samples drawn from the top of the bed were not different to those drawn from the bottom. It can be concluded that the ordered mix is very stable and no segregation of BDP and magnesium stearate occurs.

Table 10

SAMPLE	BDP 400µg/dose		DRUG ASSAY (µg /mg)		BDP100µg/dose	
	1	2	BDP 200µg/dose		1	2
Top of Cylinder						
1	17.9	17.3	8.6	8.5	4.4	4.4
2	20.5	17.1	7.5	7.6	3.5	3.5
3	16.9	17.6	7.7	7.7	3.7	3.9
4	18.0	16.9	7.7	7.8	3.8	3.9
5	17.0	17.0	7.5	9.0	4.1	4.2
6	17.2	17.1	7.6	7.8	3.9	3.8
7	17.4	17.6	7.4	8.1	3.7	3.8
8	17.2	17.1	7.6	7.7	4.2	3.8
9	16.8	17.3	7.7	7.6	4.5	3.9
10	16.9	16.5	8.3	8.0	3.6	3.8
11	16.9	18.9	7.8	8.0	4.4	4.0
12	21.1	18.1	7.9	7.9	3.9	3.9
13	17.3	17.5	7.8	7.3	3.9	4.2
14	19.4	17.1	7.7	7.7	4.2	4.1
15	18.0	19.1	7.8	8.0	4.4	3.9
Bottom of Cylinder						
Mean	17.9	17.5	7.8	7.9	4.0	3.9
SD	1.4	0.8	0.2	0.4	0.3	0.2
CV(%)	7.6	4.3	2.7	5.0	7.8	4.7

Table 11

SAMPLE	MAGNESIUM ASSAY (µg/mg)									
	BDP 400µg/dose			BDP 200µg/dose			BDP 100µg/dose			
	1	2	UN-VIBRATED	1	2	UN-VIBRATED	1	2	UN-VIBRATED	
Top of cylinder										
1	0.115	0.124	0.101	0.101	0.092	0.125	0.082	0.076	0.103	
2	0.116	0.122	0.103	0.105	0.091	0.121	0.105	0.073	0.150	
3	0.114	0.123	0.107	0.108	0.093	0.125	0.096	0.091	0.104	
4	0.113	0.119	0.109	0.100	0.093	0.118	0.107	0.085	0.101	
5	0.114	0.126	0.110	0.115	0.089	0.135	0.094	0.083	0.110	
6	0.108	0.108	0.107	0.103	0.100	0.208	0.098	0.080	0.109	
7	0.111	0.113	0.110	0.111	0.096	0.107	0.104	0.114	0.109	
8	0.118	0.108	0.108	0.107	0.096	0.101	0.102	0.076	0.102	
9	0.107	0.104	0.106	0.106	0.094	0.102	0.099	0.082	0.103	
10	0.113	0.119	0.107	0.094	0.097	0.101	0.104	0.081	0.109	
11	0.114	0.120	0.109	0.091	0.094	0.096	0.090	0.086	0.105	
12	0.116	0.117	0.105	0.083	0.093	0.098	0.100	0.084	0.107	
13	0.112	0.101	0.103	0.114	0.077	0.100	0.092	0.079	0.104	
14	0.115	0.104	0.107	0.081	0.095	0.097	0.091	0.072	0.107	
15	0.106	0.097	0.102	0.080	0.076	0.100	0.086	0.085	0.105	
Bottom of Cylinder										
Mean	0.113	0.114	0.106	0.100	0.092	0.116	0.097	0.083	0.109	
SD	0.003	0.009	0.003	0.012	0.007	0.028	0.007	0.010	0.012	
(CV%)	3.1	8.2	2.7	11.6	7.3	24.6	7.6	12.0	10.9	

Example 9Fine particle delivery of magnesium stearate

A batch of BDP 400 μg /shot powder was prepared by mixing of the drug and the carrier (lactose/magnesium stearate 99.75/0.25% w/w) under the conditions reported in Example 1. Devices were filled with the mixture and the fine particle delivery of magnesium stearate was determined using a TSI apparatus. The results are reported in Table 12.

Table 12

	Shot weight (mg)	Total Mg stearate (%)	Total Mg stearate (µg)	Mg stearate stage 2 (µg)
Mean	26.4	0.259	68	19
S.D.	0.31	0.017	4.18	2.39
CV%	1.18	6.52	6.13	12.5

Considering the low concentration of magnesium stearate in the formulation and the quantity found in stage 2 of TSI, the amount to be respirable will be very low.

This amount has been demonstrated to be safe after toxicity studies in dog.

Furthermore, acute and long term tolerance trials were carried out to evaluate toxicity of magnesium stearate in humans.

In the former, 18 healthy volunteers, included in a double blind randomised controlled cross-over design study, received a single dose containing 25.72 mg of lactose and 0.065 mg of magnesium stearate *via* Pulvinal® inhaler. The introduction of 0.25 % magnesium stearate in powdery pharmaceutical formulation resulted to be safe.

In the long term randomised, controlled, parallel group study, the safety of magnesium stearate as a carrier was compared to that of lactose. 28 Mild asthmatic patients were treated for 3 months with 400µg BDP b.i.d. delivered either with Pulvinal®, containing 0.065 mg of magnesium stearate per dose, or another commercially available DPI, containing 25.536 mg of lactose per dose. Bronchial biopsies and broncho-alveolar lavages performed at the beginning and at the end of trial did not evidence accumulation of magnesium in bronchi or in alveolar cells either in Pulvinal® or control group.

Claims

1. A powder for use in a dry powder inhaler, the powder including an active ingredient and a carrier, the carrier further including a percentage of a lubricant comprised between 0.05 and 0.5 by weight wherein the lubricant particles at least partially coat the carrier particles surface.
2. A powder according to claim 1, wherein the lubricant is selected from magnesium stearate, stearic acid, sodium lauryl sulphate, sodium stearyl fumarate, stearyl alcohol, sucrose monopalmitate and sodium benzoate.
3. A powder according to claim 2 wherein the carrier particles are coated with 0.10 to 0.25% by weight of magnesium stearate.
4. A powder according to claim 3, wherein the carrier particles are coated with 0.25% by weight of magnesium stearate.
5. A powder according to claims 2-4 wherein magnesium stearate is a crystalline or amorphous material.
6. A powder according to claims 2-5 wherein magnesium stearate is of animal or vegetal origin.
7. A powder according to any preceding claim wherein the carrier particles are comprised of one or more crystalline sugars.
8. A powder according to claims 1-7 wherein the carrier particles are made of α -lactose monohydrate.
9. A powder according to any preceding claim wherein the carrier particles have a particle size which lies between 20 and 1000 μm .
10. A powder according to claims 9 wherein the carrier particles have a particle size which lies between 90 and 150 μm .
11. A powder according to any preceding claim wherein at least 50% of the lubricant has a particle size more than 4 μm .

12. A powder according to any preceding claim wherein the lubricant is magnesium stearate and has a specific surface area which lies in the range 0.5-2.5 m²/g measured by Malvern.
13. A powder according to any preceding claim wherein the active ingredient has a particle size less than 10 µm, preferably less than 6 µm.
14. A powder according to any preceding claim wherein the active ingredient includes steroids.
15. A powder according to claim 14 wherein the active ingredient is beclometasone dipropionate or budesonide and its epimers or flunisolide.
16. A powder according to any of claims 1 to 13 wherein the active ingredient includes a β₂-agonist selected from salbutamol, formoterol, salmeterol, terbutaline and their salts.
17. A powder according to claim 16 wherein the active ingredient includes salbutamol base
18. A powder according to any of claims 1 to 13 wherein the active ingredient includes ipratropium bromide.
19. A carrier for use in a powder according to any of claims 1-18, made of carrier particles and 0.05-0.5% by weight of lubricant particles at least partially coating the carrier particles surface.
20. A method for producing the carrier according to claim 19, the method including the step of mixing the carrier particles with 0.05-0.5% by weight of lubricant in order to coat the highest as possible percentage of carrier particles surface, thus achieving an increase of the fine particle dose.
21. A method according to claim 20 wherein the carrier particles and lubricant particles are mixed for between 2 min and 480 min.
22. A method according to claims 20 and 21 wherein the carrier particles and lubricant particles are mixed using a rotating body mixer or a

stationary body mixer with a rotating mixing blade or a high-speed mixer

23. A method according to any one of claims 20-22 wherein the mixer is a tumbling blender rotating at 5-100 r.p.m.

24. A method according to any one of claims 20-23 wherein the water contact angle of the coated carrier particles is at least 30°.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 99/01449

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K9/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 23485 A (CO ORDINATED DRUG DEV ;STANIFORTH JOHN NICHOLAS (GB)) 8 August 1996 (1996-08-08) cited in the application page 45 -page 46; example 8 page 57 -page 69; example 13 ---	1-24
A	US 3 145 146 A (LIEBERMANN H. ET AL) 18 August 1964 (1964-08-18) column 4; example 11 ---	1-24
A	WO 87 05213 A (CHIESI FARMA SPA) 11 September 1987 (1987-09-11) cited in the application page 6, line 9 - line 24 ---	1-24
-/--		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"Z" document member of the same patent family

Date of the actual completion of the international search

26 November 1999

Date of making of the international search report

02/12/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Boulois, D

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 99/01449

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>MALAMATARIS, S. ET AL: "Effect of temperature on the tensile strength of lactose coated with fatty acids. Part 2. Tablets"</p> <p>POWDER TECHNOL. (1981), 28(1), 35-42 , XP000852784</p> <p>the whole document</p> <p>-----</p>	1-24

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 99/01449

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9623485 A	08-08-1996	AU 699131 B	26-11-1998
		AU 4545696 A	21-08-1996
		BG 101858 A	30-04-1998
		BR 9607490 A	23-12-1997
		CA 2211874 A	08-08-1996
		CZ 9702443 A	14-01-1998
		EP 0806938 A	19-11-1997
		FI 973151 A	30-09-1997
		HU 9802209 A	01-02-1999
		JP 10513174 T	15-12-1998
		NO 973502 A	30-09-1997
		NZ 300654 A	25-02-1999
		PL 321572 A	08-12-1997
		SK 103697 A	14-01-1998
		ZA 9600721 A	19-08-1996
US 3145146 A	18-08-1964	GB 974917 A	
WO 8705213 A	11-09-1987	IT 1204826 B	10-03-1989
		AT 94755 T	15-10-1993
		AU 597964 B	14-06-1990
		AU 7164587 A	28-09-1987
		CA 1297012 A	10-03-1992
		DE 3787502 D	28-10-1993
		DE 3787502 T	20-01-1994
		EP 0239798 A	07-10-1987
		EP 0258356 A	09-03-1988
		FI 874710 A, B	26-10-1987
		GR 88300017 T	18-10-1988
		GR 3000879 T	15-11-1991
		JP 63502895 T	27-10-1988
		NO 874590 A	30-12-1987
		NZ 219484 A	27-10-1989
		ZA 8701523 A	24-08-1987